Overview

Flavopiridol in Treating Patients With Recurrent Prostate Cancer

Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of flavopiridol in treating patients with recurrent prostate cancer after hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Alvocidib